Physician profile
Jolem Will
NPI 1043032006
$1,618.29
in general payments reported to CMS, 2019-2025
26 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247 · Education: $371.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.33 |
| Education | $370.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $408.70 | 2025 | Vyloy |
| Novartis Pharmaceuticals Corporation | $117.92 | 2025 | |
| Janssen Biotech, INC. | $114.28 | 2025 | Talvey, Rybrevant, Erleada |
| Geron Corporation | $97.12 | 2025 | Rytelo |
| Bayer Healthcare Pharmaceuticals INC. | $94.14 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.12 | 2025 | Iclusig, Alunbrig, Ninlaro |
| Incyte Corporation | $89.01 | 2025 | Jakafi, Pemazyre, Zynyz |
| Merck Sharp & Dohme LLC | $74.52 | 2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $64.54 | 2025 | |
| Tersera Therapeutics LLC | $61.68 | 2025 | Zoladex |
| Daiichi Sankyo INC. | $39.06 | 2025 | Enhertu |
| Lilly USA, LLC | $34.44 | 2025 | Jaypirca, Retevmo, Verzenio |
| Abbvie INC. | $31.61 | 2025 | |
| Taiho Oncology, INC. | $31.09 | 2025 | |
| Pharmacosmos Therapeutics INC. | $28.89 | 2025 | Monoferric |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $26.66 | 2025 | Libtayo |
| Beone Medicines USA, INC. | $26.04 | 2025 | Brukinsa |
| Genentech USA, INC. | $24.67 | 2025 | Venclexta |
| Fennec Pharmaceuticals, INC. | $24.52 | 2025 | Fyarro |
| Glaxosmithkline, LLC. | $22.96 | 2025 | Jemperli, Zejula |
| Eisai INC. | $22.73 | 2025 | |
| Recordati_rare_diseases_inc. | $20.96 | 2025 | Enjaymo |
| Novocure INC. | $19.67 | 2025 | Optune Lua (Novottf-200t) |
| Syndax Pharmaceuticals, INC. | $17.88 | 2025 | |
| Servier Pharmaceuticals LLC | $17.23 | 2025 | |
| Emd Serono, INC. | $16.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jolem Will listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.